Cwm LLC Sells 8,899 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Cwm LLC decreased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 3.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 241,262 shares of the company’s stock after selling 8,899 shares during the quarter. Cwm LLC owned about 0.10% of Maravai LifeSciences worth $1,580,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in MRVI. China Universal Asset Management Co. Ltd. raised its stake in Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after buying an additional 1,662 shares during the last quarter. Signaturefd LLC raised its stake in shares of Maravai LifeSciences by 99.9% in the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock worth $34,000 after purchasing an additional 1,681 shares during the last quarter. Pinnacle Associates Ltd. purchased a new position in shares of Maravai LifeSciences in the fourth quarter worth $69,000. Ieq Capital LLC purchased a new position in shares of Maravai LifeSciences in the third quarter worth $110,000. Finally, Advisor Partners II LLC purchased a new position in shares of Maravai LifeSciences in the third quarter worth $115,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $7.70 on Friday. The company has a current ratio of 8.00, a quick ratio of 7.41 and a debt-to-equity ratio of 0.70. Maravai LifeSciences Holdings, Inc. has a one year low of $4.52 and a one year high of $16.62. The stock has a fifty day moving average of $7.78 and a 200 day moving average of $6.68.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $74.14 million for the quarter, compared to analysts’ expectations of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. Analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRVI has been the subject of several recent analyst reports. Royal Bank of Canada boosted their price target on Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Craig Hallum initiated coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Stifel Nicolaus decreased their price target on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.